Ermium Therapeutics to present promising preclinical data highlighting the therapeutic potential of Ermium immunomodulators for the treatment of systemic lupus erythematosus at the annual ACR Convergence 2022 conference

Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today that Dr Annegret Van der Aa, CSO/CDO will be presenting promising preclinical data on Ermium immunomodulators for the treatment of systemic lupus erythematosus (SLE) and other type I interferon-driven diseases at the ACR Convergence 2022 conference to be held between November 10th – 14th in Philadelphia, US, and virtually.